Related Experiment Videos
Two unusual complex translocations in Ph-positive chronic myeloid leukemia
Cancer Genetics and Cytogenetics
|August 1, 1987
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
O. Harold Warwick: Canada's first medical oncologist.
Current oncology (Toronto, Ont.)·2011
Vera Peters and the conservative management of early-stage breast cancer.
Current oncology (Toronto, Ont.)·2010
Blood transfusion in Canada: the early years.
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2008
Vera Peters and the curability of Hodgkin disease.
Current oncology (Toronto, Ont.)·2008
WITHDRAWN: Sex differences in the expression of sodium/calcium exchanger influence the arrhythmia phenotype in the long QT syndrome type 2.
British journal of pharmacology·2008
A pericentric inv(9)(p22q34) of the der(9)t(9;22)(q34;q11.2) is a recurrent secondary anomaly in Ph-positive leukemia.
Cancer genetics and cytogenetics·2010
Translocation (3;8)(q27;q24) in two cases of triple hit lymphoma.
Cancer genetics and cytogenetics·2010
Screening for DNA copy number aberrations in mucinous adenocarcinoma arising from the minor salivary gland: two case reports.
Cancer genetics and cytogenetics·2010
Screening for common copy-number variants in cancer genes.
Cancer genetics and cytogenetics·2010
Trisomy 17 in congenital plexiform (multinodular) cellular schwannoma.
Cancer genetics and cytogenetics·2010
Chromosomal alterations in Malaysian patients with nasopharyngeal carcinoma analyzed by comparative genomic hybridization.
Cancer genetics and cytogenetics·2010
Development of cecal volvulus after redo pancreas transplantation.
Journal of surgical case reports·2026
Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.
Iranian journal of otorhinolaryngology·2026
Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.
Research and practice in thrombosis and haemostasis·2026